Search Results

You are looking at 101 - 110 of 153 items for :

  • "renal cell carcinoma" x
Clear All
Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes

than 64 years with recurrent or metastatic SCCHN. 291 Kidney Cancer: Surgical resection remains an effective treatment for patients with localized renal cell carcinoma (RCC). However, in a recent study, Lane et al. 292 reported that surgical

Full access

Rishi Jain, Michelle J. Savage, Andrea D. Forman, Reetu Mukherji and Michael J. Hall

. Neumann HP Bender BU Berger DP . Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma . J Urol 1998 ; 160 : 1248 – 1254 .

Full access

Ravi A. Madan, Thomas Schwaab and James L. Gulley

( Suppl 2 ): 14639 – 14645 . 2 Schwaab T Ernstoff MS . Therapeutic vaccines in renal cell carcinoma . Therapy 2011 ; 4 : 369 – 377 . 3 So-Rosillo R Small EJ . Sipuleucel-T (APC8015) for prostate cancer . Expert Rev Anticancer

Full access

Kamel Izeradjene and Sunil R. Hingorani

dendritic cells on renal cell carcinoma . Anticancer Res 2002 ; 22 : 4281 – 4284 . 107. Dirkx AE Oude Egbrink MG Wagstaff J Griffioen AW . Monocyte/macrophage infiltration in tumors: modulators of angiogenesis . J Leukoc Biol 2006 ; 80

Full access

Carlos Camps, Joan Albanell, Antonio Antón, Enrique Aranda, Alfredo Carrato, Javier Cassinello, Daniel Castellano, Juan J. Cruz, Pilar Garrido, Vicente Guillem, Cristina Grávalos, Guillermo López, César Llorente, Antonio Lorenzo, Ana Lluch, Emilio Ignacio and Eduardo Díaz-Rubio

systematic review . Ann Surg Oncol 2013 ; 20 : 381 – 398 . 21. Wood L Bjarnason GA Black PC . Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma . J Oncol Pract 2013

Full access

Michael Cecchini, Jeffrey Sklar and Jill Lacy

rare, but have been described in cancers of the pancreas, head and neck, esophagus, biliary tract, prostate, colon, and ovaries, as well as in sarcomas and papillary renal cell carcinoma. 12 – 18 Mutations in EGFR are present in rare cases of

Full access

Lillie D. Shockney

small percentage of patients with certain cancers (eg, colon cancer, renal cell carcinoma, some sarcomas) that recur distantly with oligometastatic disease may be able to undergo surgery for a possible cure. 11 , 12 In many clinical situations, however

Full access

Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky and Karen L. Reckamp

without acquired resistance in the lung. The evolution of the patient’s lung tumor histology from adenocarcinoma to squamous cell carcinoma is also of interest. Tumor heterogeneity leading to cancer evolution is a complex process, as shown in renal cell

Full access

Nikhil Khandelwal, Ian Duncan, Tamim Ahmed, Elan Rubinstein and Cheryl Pegus

Web site . Available at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcmanual_v4_10-4-99.pdf . Assessed May 20, 2011 . 15 Eisen T Oudard S Gravis G . Sorafenib for older patients with renal cell carcinoma

Full access

Eric T. Wong, Shiva Gautam, Christopher Malchow, Melody Lun, Edward Pan and Steven Brem

dose only offered an improvement in median time to progression but not response rate or overall survival. 12 In metastatic renal cell carcinoma, no difference was seen between bevacizumab doses of 3 and 10 mg/kg with respect to response rate, time to